Free Trial

Tarsus Pharmaceuticals (TARS) Competitors

Tarsus Pharmaceuticals logo
$54.49 +0.28 (+0.52%)
As of 03:25 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

TARS vs. ROIV, GRFS, LEGN, RVMD, RYTM, RNA, NUVL, ABVX, AXSM, and CRSP

Should you be buying Tarsus Pharmaceuticals stock or one of its competitors? The main competitors of Tarsus Pharmaceuticals include Roivant Sciences (ROIV), Grifols (GRFS), Legend Biotech (LEGN), Revolution Medicines (RVMD), Rhythm Pharmaceuticals (RYTM), Avidity Biosciences (RNA), Nuvalent (NUVL), Abivax (ABVX), Axsome Therapeutics (AXSM), and CRISPR Therapeutics (CRSP). These companies are all part of the "pharmaceutical products" industry.

Tarsus Pharmaceuticals vs. Its Competitors

Tarsus Pharmaceuticals (NASDAQ:TARS) and Roivant Sciences (NASDAQ:ROIV) are both mid-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, risk, valuation, profitability, analyst recommendations, dividends, earnings and institutional ownership.

Tarsus Pharmaceuticals currently has a consensus price target of $66.67, suggesting a potential upside of 22.34%. Roivant Sciences has a consensus price target of $16.50, suggesting a potential upside of 39.77%. Given Roivant Sciences' stronger consensus rating and higher possible upside, analysts clearly believe Roivant Sciences is more favorable than Tarsus Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Tarsus Pharmaceuticals
0 Sell rating(s)
1 Hold rating(s)
5 Buy rating(s)
1 Strong Buy rating(s)
3.00
Roivant Sciences
0 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
2 Strong Buy rating(s)
3.25

Tarsus Pharmaceuticals has higher revenue and earnings than Roivant Sciences. Tarsus Pharmaceuticals is trading at a lower price-to-earnings ratio than Roivant Sciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Tarsus Pharmaceuticals$182.95M12.57-$115.55M-$2.33-23.39
Roivant Sciences$29.05M276.25-$171.98M-$0.70-16.86

90.0% of Tarsus Pharmaceuticals shares are owned by institutional investors. Comparatively, 64.8% of Roivant Sciences shares are owned by institutional investors. 9.0% of Tarsus Pharmaceuticals shares are owned by company insiders. Comparatively, 10.8% of Roivant Sciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

In the previous week, Tarsus Pharmaceuticals had 3 more articles in the media than Roivant Sciences. MarketBeat recorded 14 mentions for Tarsus Pharmaceuticals and 11 mentions for Roivant Sciences. Tarsus Pharmaceuticals' average media sentiment score of 0.98 beat Roivant Sciences' score of 0.49 indicating that Tarsus Pharmaceuticals is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Tarsus Pharmaceuticals
5 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Roivant Sciences
6 Very Positive mention(s)
2 Positive mention(s)
0 Neutral mention(s)
1 Negative mention(s)
1 Very Negative mention(s)
Neutral

Tarsus Pharmaceuticals has a net margin of -31.13% compared to Roivant Sciences' net margin of -2,111.79%. Roivant Sciences' return on equity of -15.90% beat Tarsus Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Tarsus Pharmaceuticals-31.13% -32.36% -21.04%
Roivant Sciences -2,111.79%-15.90%-14.95%

Tarsus Pharmaceuticals has a beta of 0.79, indicating that its share price is 21% less volatile than the S&P 500. Comparatively, Roivant Sciences has a beta of 1.15, indicating that its share price is 15% more volatile than the S&P 500.

Summary

Roivant Sciences beats Tarsus Pharmaceuticals on 10 of the 17 factors compared between the two stocks.

Get Tarsus Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for TARS and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TARS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

TARS vs. The Competition

MetricTarsus PharmaceuticalsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$2.30B$3.13B$5.71B$9.79B
Dividend YieldN/A2.21%3.77%4.10%
P/E Ratio-23.3920.9230.9125.28
Price / Sales12.57232.70404.2188.50
Price / CashN/A41.5625.2228.45
Price / Book9.289.779.536.01
Net Income-$115.55M-$54.74M$3.26B$265.34M
7 Day Performance8.83%8.37%4.66%2.89%
1 Month Performance25.99%7.94%5.35%1.61%
1 Year Performance112.11%18.27%32.14%25.61%

Tarsus Pharmaceuticals Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
TARS
Tarsus Pharmaceuticals
1.818 of 5 stars
$54.49
+0.5%
$66.67
+22.3%
+111.0%$2.30B$182.95M-23.3950
ROIV
Roivant Sciences
2.9818 of 5 stars
$11.17
-2.8%
$16.50
+47.7%
+5.9%$7.81B$29.05M-44.68860News Coverage
GRFS
Grifols
3.7967 of 5 stars
$10.60
-0.6%
$10.30
-2.8%
+51.8%$7.33B$7.81B9.0623,822Short Interest ↑
LEGN
Legend Biotech
3.7324 of 5 stars
$36.24
-2.1%
$73.33
+102.4%
-34.1%$6.80B$627.24M-61.422,609Earnings Report
RVMD
Revolution Medicines
4.1682 of 5 stars
$34.70
-0.9%
$68.82
+98.3%
-15.2%$6.54B$11.58M-7.71250News Coverage
Analyst Forecast
RYTM
Rhythm Pharmaceuticals
3.7461 of 5 stars
$94.31
+2.5%
$101.57
+7.7%
+111.8%$6.11B$130.13M-31.33140
RNA
Avidity Biosciences
3.1796 of 5 stars
$45.75
-1.2%
$67.00
+46.4%
+3.3%$5.96B$10.90M-15.25190Positive News
Insider Trade
NUVL
Nuvalent
3.048 of 5 stars
$74.95
+1.1%
$119.60
+59.6%
+6.3%$5.32BN/A-15.3040
ABVX
Abivax
3.5305 of 5 stars
$69.00
-1.6%
$92.33
+33.8%
+549.2%$5.30BN/A0.0061Short Interest ↑
AXSM
Axsome Therapeutics
4.7574 of 5 stars
$103.96
-0.8%
$178.00
+71.2%
+26.7%$5.23B$385.69M-20.50380Positive News
CRSP
CRISPR Therapeutics
3.203 of 5 stars
$55.41
+0.7%
$71.60
+29.2%
+24.8%$5.00B$37.31M-10.20460

Related Companies and Tools


This page (NASDAQ:TARS) was last updated on 8/18/2025 by MarketBeat.com Staff
From Our Partners